Table 1.
Patients’ characteristics
| Gene expression | Flow cytometry | Chemotaxis | ||||
|---|---|---|---|---|---|---|
| non‐SS (n = 9) | pSS (n = 9) | HC (n = 11) | pSS (n = 17) | HC (n = 6) | pSS (n = 10) | |
| Female gender, n (%) | 8 (89) | 8 (89) | 11 (100) | 17 (100) | 6 (100) | 10 (100) |
| Age, years (Mean ± SD) | 53.3 ± 7.5 | 43.7 ± 19.7 | 43.4 ± 12.3 | 54.6 ± 13.2 | 54.3 ± 6.8 | 58.6 ± 11.0 |
| Anti‐Ro/SSA positive, n (%) | 2 (22) | 9 (100) | ‐ | 16 (94) | ‐ | 8 (80) |
| Anti‐La/SSB positive, n (%) | 0 (0) | 3 (33) | ‐ | 9 (53) | ‐ | 6 (60) |
| ANA positive, n (%) | 1 (11) | 7 (78) | ‐ | 13 (76) | ‐ | 8 (80) |
| Lymphocytic focus score (foci/4 mm2) | 0 (0‐0) | 3.0 (1.5‐5.0) | ‐ | 2.0 (1.4‐2.7) | ‐ | 2 (1.8‐3) |
| IgA positive plasma cells (%) | >70 | 43 (16‐50) | ‐ | 38 (25‐51) | ‐ | 33 (19‐46) |
| Schirmer (mm/5 min) | 1.5 (1.0‐5.0) | 4.0 (0.8‐17.0) | ‐ | 3.5 (0.4‐12.3) | ‐ | 4.5 (0.5‐10) |
| Serum IgG (g/L) | 11.4 (11.0‐12.4) | 17.4 (10.4‐28.5) | ‐ | 17.2 (13.8‐19.7) | ‐ | 13.6 (12.0‐17.0) |
| ESR (mm/h) | 6 (3‐21) | 14 (10‐52) | ‐ | 22 (13‐33) | ‐ | 13 (12‐34) |
| ESSDAI score (0‐123) | ‐ | ‐ | ‐ | 6 (5‐8) | ‐ | 6 (2‐8) |
| ESSPRI score (0‐10) | ‐ | ‐ | ‐ | 6.5 (5‐7) | ‐ | 5 (3‐7) |
| Immunosuppressants | 0 | 1 | ‐ | 3 | ‐ | 2 |
| Hydroxychloroquine | ‐ | 0 | ‐ | 3 | ‐ | 1 |
| Other | ‐ | 1 | ‐ | 0 | ‐ | 1 |
Median (IQR, interquartile range) is shown unless specified otherwise.
Abbreviations: ESR, erythrocyte sedimentation rate; ESSDAI, EULAR Sjögren's syndrome disease activity index; ESSPRI, EULAR Sjögren's syndrome patient reported index; HC, healthy controls; non‐SS, non‐Sjögren's sicca; pSS, primary Sjögren's syndrome.